Toxicity clinical trials at UC Davis
1 research study open to eligible people
An Experimental Comparison Study of Envarsus ® XR and Tacrolimus IR for Elderly Kidney Transplant Patients
“This study will test any differences in neurological side effects between two FDA indicated medications to prevent rejection of your kidney.”
open to eligible people ages 65 years and up
Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related toxicities. Therefore, the investigators hypothesize that by transitioning patients from tacrolimus immediate release to Envarsus ®, the peak-dose effect will be eliminated or attenuated, leading to a significant decrease in neurocognitive toxicities in the older patient population.
Our lead scientists for Toxicity research studies include Ling-Xin Chen, MD.